Ann: onCARlytics to be showcased in three abstracts at SITC, page-83

Bav,

" know this is a. only pre-clinical and b. is there interest with BP? "

There have been deals made after pre-clinicals when Big Pharma saw sufficient and encouraging data.

While some here criticise IMU for "just" having data atm and no money deals it proves how important data are.

What quality are IMU's data made of?

When PH / IMU licenced Her-Vaxx and Prof K.'s B-Vaxx / PD1-Vaxx they had exciting pre-clinical data based on safety and efficacy. Using modelling the expectations were high and so far - have been met or exceeded. That speaks for the IMU platforms and the likelihood of replicating pre-clinical results in clinical trials.

If the onCarlytics pre-clinical results have the same or better quality then BP must conclude that the clinical results will be " Da BomB ".
That way there could be pre-clinical deals based on IMU's remarkable track record.

Low volume over the last days apart of the director's conversion selling, maybe the big guys expecting big things too and have stopped selling big quantities.

GLTA